Concert Pharmaceuticals Inc (NASDAQ:CNCE) Director Richard Aldrich sold 30,000 shares of the firm’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $19.35, for a total transaction of $580,500.00. Following the transaction, the director now directly owns 286,975 shares of the company’s stock, valued at approximately $5,552,966.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Richard Aldrich also recently made the following trade(s):
- On Tuesday, January 16th, Richard Aldrich sold 31,236 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $19.14, for a total transaction of $597,857.04.
Shares of Concert Pharmaceuticals Inc (CNCE) opened at $19.61 on Monday. Concert Pharmaceuticals Inc has a 12-month low of $8.61 and a 12-month high of $30.71. The firm has a market cap of $446.57, a price-to-earnings ratio of 5.27 and a beta of 1.67.
Several equities analysts have recently issued reports on the stock. BidaskClub raised shares of Concert Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 9th. Mizuho downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $23.00 price target for the company. in a research note on Friday, January 12th. TheStreet upgraded shares of Concert Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Monday, January 8th. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Concert Pharmaceuticals in a research report on Friday, October 20th. Finally, UBS Group set a $34.00 price objective on shares of Concert Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 19th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. Concert Pharmaceuticals presently has an average rating of “Hold” and an average target price of $24.33.
Several institutional investors and hedge funds have recently bought and sold shares of CNCE. SG Americas Securities LLC acquired a new stake in Concert Pharmaceuticals in the third quarter worth $153,000. Alliancebernstein L.P. acquired a new stake in Concert Pharmaceuticals in the second quarter worth $174,000. The Manufacturers Life Insurance Company grew its holdings in Concert Pharmaceuticals by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 287 shares during the period. Princeton Capital Management Inc. acquired a new stake in Concert Pharmaceuticals in the third quarter worth $215,000. Finally, OxFORD Asset Management LLP grew its holdings in Concert Pharmaceuticals by 42.1% in the second quarter. OxFORD Asset Management LLP now owns 19,711 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 5,835 shares during the period. Institutional investors own 65.35% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Concert Pharmaceuticals Inc (CNCE) Director Richard Aldrich Sells 30,000 Shares” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://sportsperspectives.com/2018/01/22/concert-pharmaceuticals-inc-cnce-director-richard-aldrich-sells-30000-shares.html.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.